TABLE 2.

Characteristics of patients harboring defined clones of toxin-producing MRSA

CharacteristicST80 European clone (n = 91)ST5 Geraldine clonePb
Phenotype 2 (n = 146)Phenotype 3 (n = 42)Total (n = 190c)
Proportion (%)
    Among S. aureus strains (n = 34,970)0.260.420.120.54<.001
    Among MRSA strains (n = 7,253)1.252.010.582.61<.001
Days in hospital before sampling, median (10p-90pa)0 (0-2)0 (0-21)1 (0-12)0 (0-19)0.001
Age, median (10p-90p)26.0 (2-64)48.5 (3-94)53.5 (1-84)49.5 (2-84)<.001
Male gender48 (53%)68 (47%)24 (57%)94 (49%)0.61
Type of sample
    Deep cutaneous44 (48%)8 (5%)3 (7%)11 (6%)<.001
    Superficial31 (34%)54 (37%)17 (41%)71 (37%)0.69
    Bloodstream infection9 (6%)3 (7%)12 (6%)0.01
    Respiratory7 (8%)39 (27%)10 (24%)51 (27%)<.001
    Urine11 (8%)1 (2%)12 (6%)0.01
    Other9 (10%)25 (17%)8 (19%)33 (17%)0.11
Toxic shock syndromed1 (1%)13 (9%)6 (14%)19 (10%)0.007
Community acquired73 (80%)65 (45%)21 (50%)87 (46%)<.001
Linked to another case6 (7%)2 (1%)02 (1%)0.01
Antibiotic treatment41 (45%)85 (62%)20 (48%)107 (56%)0.06
Surgical treatment36 (40%)16 (11%)5 (12%)21 (11%)<.001
Associated susceptibility of strains
    Erythromycin64 (70%)105 (72%)33 (79%)140 (74%)0.57
    Tetracycline18 (22%)121 (83%)38 (90%)161 (85%)<.001
    Rifampin91 (100%)136 (93%)41 (98%)179 (94%)0.02